PRTG vs. DRUG, NIVF, GBNHF, TMDIF, TFFP, NEXI, TCON, RNAZ, ARTL, and CPHI
Should you be buying Portage Biotech stock or one of its competitors? The main competitors of Portage Biotech include Bright Minds Biosciences (DRUG), NewGenIvf Group (NIVF), Greenbrook TMS (GBNHF), Titan Medical (TMDIF), TFF Pharmaceuticals (TFFP), NexImmune (NEXI), TRACON Pharmaceuticals (TCON), TransCode Therapeutics (RNAZ), Artelo Biosciences (ARTL), and China Pharma (CPHI). These companies are all part of the "medical" sector.
Bright Minds Biosciences (NASDAQ:DRUG) and Portage Biotech (NASDAQ:PRTG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.
In the previous week, Bright Minds Biosciences had 1 more articles in the media than Portage Biotech. MarketBeat recorded 2 mentions for Bright Minds Biosciences and 1 mentions for Portage Biotech. Portage Biotech's average media sentiment score of 1.32 beat Bright Minds Biosciences' score of 0.23 indicating that Bright Minds Biosciences is being referred to more favorably in the media.
Bright Minds Biosciences has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.
Portage Biotech has a consensus price target of $8.50, indicating a potential upside of 3,183.12%. Given Bright Minds Biosciences' higher probable upside, analysts clearly believe Portage Biotech is more favorable than Bright Minds Biosciences.
Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.
Portage Biotech received 13 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users.
40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 42.1% of Portage Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Portage Biotech's return on equity of -77.40% beat Bright Minds Biosciences' return on equity.
Summary
Bright Minds Biosciences beats Portage Biotech on 9 of the 13 factors compared between the two stocks.
Get Portage Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Portage Biotech Competitors List
Related Companies and Tools
